GE HealthCare Announces US Launch Of Longer Half-Life PET MPI Agent For Ischemia Detection

Flyrcado’s Long Half-Life And Stress-Test Compatibility Could Reshape Cardiac PET As GE HealthCare Targets 2026 For Its Photon-Counting CT Launch.

GE HealthCare is pursuing a dual-front imaging strategy with its PET MIP agent Flyrcado for detecting artery disease: It lasts longer than current PET scan tracers and allows patients to do treadmill-based stress tests alongside the scan.

Flyrcado’s CMS pass-through status, which lasts up to three years, ensures temporary reimbursement above the standard outpatient payment rate.
Key Takeaways
  • Flyrcado, GEHC’s new cardiac PET imaging agent, has CMS pass-through status, which lasts up to three years, ensures temporary reimbursement above the standard outpatient payment rate and is expected to generate $30m in 2025 and up to $500m by 2028.

GE HealthCare’s CEO has high expectations for Flyrcado, a positron emission tomography myocardial perfusion imaging (PET MPI) agent for detecting...

More from Diagnostic Imaging

More from Medtech Insight

Finland Cracks Down On Software That Needs Regulating As A Medical Devices

 

Finland has initiated a project to improve the effectiveness of the monitoring of software intended for medical use and to ensure that software placed on its market meets the requirements set for it. 

Milner Pitch Day: Multiomic Pathology, Microcancer Avatars And Cell Morphology Intelligence

 

The Milner Institute, the on-campus hub for start-up acceleration at Cambridge University, hosted its annual Pitch Day on July 1. Start-ups Panakeia, PathwayBio and Sentinal4D presented diagnostic technologies.

Investors Urged To Prioritize Patient Engagement To Ensure Clients’ Products Succeed

 

To succeed in medtech, investors must focus on patient outcomes. Gilde Healthcare says involving patients boosts product effectiveness, access and market success — making it a smart strategy in today’s strained healthcare systems.